Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Losartan for liver fibrosis in non-alcoholic steatohepatitis
2009-015166-62Phase 3Completed
- Sponsor
- Newcastle Hospitals NHS Foundation Trust
- Start
- Oct 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in metabolic dysfunction-associated steatohepatitis (MASH) and hepatic fibrosis comparing Losartan with Placebo (2 arms). Primary endpoint: Change in Kleiner fibrosis score. Started Oct 2010; status: completed.
02
Drugs
losartan
03
Conditions
metabolic dysfunction-associated steatohepatitis (MASH)hepatic fibrosis
Beyond the preview
Go deeper on 2009-015166-62.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-015166-62.